In situ forming implantsselection of the most suitable polymer for the administration of CBD
- Lozza I 2
- Cristina Martín Sabroso 12
- Ana Isabel Torres Suárez 12
- Ana Isabel Fraguas Sánchez 12
- 1 Institute of Industrial Pharmacy, Complutense University of Madrid.
- 2 Department of Pharmaceutics and Food Technology, Complutense University of Madrid.
ISSN: 2660-6356
Año de publicación: 2021
Título del ejemplar: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA
Volumen: 2
Número: 2
Páginas: 191-192
Tipo: Artículo
Otras publicaciones en: RESCIFAR Revista Española de Ciencias Farmacéuticas
Resumen
In situ forming implants (IFIs) that are typically made of a drug, solvent, and a biocompatible polymer, offer an interesting potential for parenteral controlled drug delivery. Also, they have the advantages of a non-complicated preparation and an easy administration using conventional subcutaneous needles. In fact, several IFIs containing doxycycline or leuprorelin are currently approved by FDA and/or EMA. Cannabidiol (CBD), the main non-psychotropic cannabinoid, appears as a potential anticancer drug, but it shows high lipophilicity and instability that complicates its handling and dosing and restricts its use by a parenteral route. The use of IFIs could be a good strategy to develop long-active CBD formulations. The objective of this work was to evaluate, among several biocompatible and biodegradable polymer, the most suitable to develop CBD-ISFIs.